CytRx Corp (CYTR)

0.43
NASDAQ : Health Care
Prev Close 0.43
Day Low/High 0.42 / 0.45
52 Wk Low/High 0.36 / 1.00
Avg Volume 5.33M
Exchange NASDAQ
Shares Outstanding 165.83M
Market Cap 71.31M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CytRx Corporation Announces Receipt Of NASDAQ Listing Determination

CytRx Corporation Announces Receipt Of NASDAQ Listing Determination

- Company to Request Hearing -

CytRx Corporation Files Preliminary Proxy Statement For Upcoming Special Meeting

CytRx Corporation Files Preliminary Proxy Statement For Upcoming Special Meeting

Company Seeks to Avoid Delisting from NASDAQ

CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic

CytRx Corporation Announces Global Strategic License With NantCell Inc. For Aldoxorubicin, An Albumin Mediated Chemotherapeutic

NantCell to Expand the Development of Aldoxorubicin into Multiple Tumor Types in Combination with Immuno-Oncology and Cell-Based Therapies

Interesting CYTR Call Options For March 2018

Investors in CytRx Corp saw new options begin trading today, for the March 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

CytRx Announces Reshaping Of Clinical And Regulatory Executive Team

- Dr. Shanta Chawla promoted to Senior Vice President of Drug Development -

CytRx Announces Update On The Regulatory Pathway For Aldoxorubicin In Soft Tissue Sarcomas

- Current Clinical and Preclinical Data Can Support Approval

Goodbye CytRx, Your Game Is Over

Goodbye CytRx, Your Game Is Over

Hope springs eternal, until it's dashed on the rocks and buried at sea.

CytRx To Present Global Phase 3 Aldoxorubicin Clinical Data In Patients With Soft Tissue Sarcomas At The 2017 American Society Of Clinical Oncology Annual Meeting

Oral Presentation Highlighting Updated and More Detailed Results from Global Phase 3 Trial in STS

CytRx Announces FDA Agreement On Regulatory Pathway To Approval For Aldoxorubicin In Soft Tissue Sarcomas

- Development Program Can Support Approval, No New Studies Requested

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1

An SEC enforcement action uncovers the deep involvement and brazen misbehavior of biotech CEOs in an illegal stock promotion scheme.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Could These 9 Drugs Gain FDA Approval in the Age of Trump?

Nine biotech and drug companies want FDA approval, but need changed standards to get it.

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The 'Gnarly 9' Biotechs Will Test the FDA's Mettle

The firms all have drugs they want the feds to bend the rules to approve.

First Week of CYTR September 15th Options Trading

First Week of CYTR September 15th Options Trading

Investors in CytRx Corp saw new options begin trading this week, for the September 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA

CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation

Law Offices of Howard G. Smith reminds investors of the upcoming  September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") reminds investors of the September 23, 2016 deadline to file a lead plaintiff motion in the class action lawsuit filed on behalf of investors who purchased or otherwise...

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation ("CytRx" or the "Company") (NASDAQ:CYTR )...

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Central District of California on behalf of investors who purchased CytRx Corporation (NASDAQ:CYTR) securities...

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm

Glancy Prongay & Murray LLP ("GPM") announces that a class action lawsuit has been filed on behalf of investors who purchased CytRx Corporation ("CytRx" or the "Company") (NASDAQ: CYTR) securities between...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CytRx Corporation ("CytRx" or the "Company") (NASDAQ: CYTR) ...

TheStreet Quant Rating: D- (Sell)